06: BioPorto’s patent rights for NGAL - opposition to the European patent
August 09 2010
Announcement no. 6
BioPorto’s patent rights for NGAL - opposition to the European patent
In continuation of BioPorto’s previous announcements about patent rights to NGAL, including announcement no. 26 of October 6, 2009, the European Patent Office has published the oppositions to the issued European NGAL cutoff patent. Oppositions to key patents in areas where other companies have an interest are not unusual. Oppositions are made with the purpose of limiting other companies’ patent rights within the respective area.
As no licensing agreements have yet come into place with companies with an interest within the NGAL area, the current opposition to the cutoff patent was anticipated. BioPorto’s cutoff patent is considered strong and the opposition to the patent is not expected to result in changes in the obtained patent rights. An opposition may proceed in several years, but the patent rights remain unchanged during this process and therefore do not alter the requirement that other companies must obtain a license to the patent or pay damages for infringement if the blocking claims of the patent are valid after an opposition is ended. The actual content of the oppositions and replies will be dealt with in cooperation with BioPorto’s patent attorneys Høiberg A/S and mentioned in BioPortos reporting on IP rights.
For further information please contact:
Thea Olesen, CEO
Christina Tønnesen, Investor Relations
Tel. +45 45 29 00 00, e-mail investor@bioporto.com
